AU3121497A - Methods of treating type i hypersensitivity using monophosphoryl lipid - Google Patents

Methods of treating type i hypersensitivity using monophosphoryl lipid

Info

Publication number
AU3121497A
AU3121497A AU31214/97A AU3121497A AU3121497A AU 3121497 A AU3121497 A AU 3121497A AU 31214/97 A AU31214/97 A AU 31214/97A AU 3121497 A AU3121497 A AU 3121497A AU 3121497 A AU3121497 A AU 3121497A
Authority
AU
Australia
Prior art keywords
mla
hypersensitivity
monophosphoryl lipid
methods
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31214/97A
Other languages
English (en)
Inventor
Jerry Dolovich
Jean S. Marshall
J. Terry Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of AU3121497A publication Critical patent/AU3121497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU31214/97A 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid Abandoned AU3121497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08645672 1996-05-14
US08/645,672 US5762943A (en) 1996-05-14 1996-05-14 Methods of treating type I hypersensitivity using monophosphoryl lipid A
PCT/US1997/007965 WO1997042947A1 (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
AU3121497A true AU3121497A (en) 1997-12-05

Family

ID=24589990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31214/97A Abandoned AU3121497A (en) 1996-05-14 1997-05-08 Methods of treating type i hypersensitivity using monophosphoryl lipid

Country Status (11)

Country Link
US (1) US5762943A (enExample)
EP (1) EP0914114B1 (enExample)
JP (1) JP4105230B2 (enExample)
AT (1) ATE249824T1 (enExample)
AU (1) AU3121497A (enExample)
CA (1) CA2252604C (enExample)
DE (1) DE69724970T2 (enExample)
DK (1) DK0914114T3 (enExample)
ES (1) ES2205231T3 (enExample)
PT (1) PT914114E (enExample)
WO (1) WO1997042947A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086928B2 (ja) * 1997-02-13 2008-05-14 大日本住友製薬株式会社 タイプ２ヘルパーｔ細胞型サイトカイン産生選択的抑制剤
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9724531D0 (en) * 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
JP2002520373A (ja) * 1998-07-14 2002-07-09 アメリカン・サイアナミド・カンパニー モノホスホリルリピドａを含有するアジュバントおよびワクチン組成物
ES2259478T3 (es) * 1998-09-18 2006-10-01 Dynavax Technologies Corporation Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
EP1671646A3 (en) * 1998-09-18 2007-08-29 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
AU781469B2 (en) * 1999-05-13 2005-05-26 Wyeth Holdings Corporation Adjuvant combination formulations
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20030105032A1 (en) * 2000-05-19 2003-06-05 Persing David H. Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds
CN1606446A (zh) 2000-05-19 2005-04-13 科里克萨有限公司 用单糖和二糖类化合物预防和治疗传染病和其他疾病的方法
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
HRP20030355A2 (en) * 2000-11-10 2005-04-30 Wyeth Holdings Corporation Adjuvant combination formulations
US20030031684A1 (en) * 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
GB0120150D0 (en) * 2001-08-17 2001-10-10 Glaxosmithkline Biolog Sa Novel compounds
DE10359351A1 (de) * 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
AU2007354917B2 (en) 2006-09-26 2013-06-06 Access To Advanced Health Institute Vaccine composition containing synthetic adjuvant
US9724271B2 (en) * 2010-04-30 2017-08-08 Allovate, Llc Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EA201691452A1 (ru) * 2014-01-21 2016-12-30 Иммьюн Дизайн Корп. Композиции для применения в лечении аллергических состояний
BR112017022585A2 (pt) 2015-05-01 2018-07-17 Nitto Denko Corporation composição de vacina de alergia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
KR900701304A (ko) * 1988-05-05 1990-12-01 루이즈 츄이 콜린스 에이미 사람 및/또는 동물용 알레르겐 탈감작제
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
JP2838800B2 (ja) * 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5286718A (en) * 1991-12-31 1994-02-15 Ribi Immunochem Research, Inc. Method and composition for ameliorating tissue damage due to ischemia and reperfusion
WO1993015766A1 (en) * 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens

Also Published As

Publication number Publication date
JP2000510844A (ja) 2000-08-22
US5762943A (en) 1998-06-09
JP4105230B2 (ja) 2008-06-25
EP0914114B1 (en) 2003-09-17
EP0914114A1 (en) 1999-05-12
PT914114E (pt) 2004-02-27
ATE249824T1 (de) 2003-10-15
ES2205231T3 (es) 2004-05-01
CA2252604A1 (en) 1997-11-20
DE69724970D1 (de) 2003-10-23
CA2252604C (en) 2009-09-08
DK0914114T3 (da) 2003-10-20
DE69724970T2 (de) 2004-07-22
WO1997042947A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
AU3121497A (en) Methods of treating type i hypersensitivity using monophosphoryl lipid
EP0735893A4 (en) CHANGING THE IMMUNE RESPONSE BY USING PAN DR BINDING PROTEINS
DE69511379D1 (en) Immunogens gegen gonadotropin releasing hormone
KR970706013A (ko) 암에 대해 면역학적 치료활성이 있는 스트레스 단백질-펩티드 복합체 (immunotherapeutic stress protein-peptide complexes against cancer)
EP1393730A3 (en) Combination chemotherapy involving topotecan and a platinum coordination compound
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
NZ241210A (en) 16alpha,17alpha-butylidenedioxy-11b, 21-dihydroxypregn-4-ene-3,20-dione derivatives substituted in either or both the 6alpha- and 9alpha- positions by fluorine; pharmaceutical compositions, methods of preparation and treatment
AU7460896A (en) Composition and methods for enhancing immune responses mediated by antigen-presenting cells
AU6705594A (en) Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation
EP0837692A4 (enExample)
NO955085L (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
AU7161098A (en) Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
AU4545096A (en) Polypeptide fragments capable of competition with streptococcus mutans antigen i/ii
FI956028A0 (fi) Estreenisteroidit ihmisen hypotalaamisen toiminnan muuttamisen neurokemiallisina initiaattoreina sekä tähän liittyvät farmaseuttiset koostumukset ja menetelmät
EP0282343A3 (en) Method to stimulate the immune response to specific antigens
EP0955366A4 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
AU3991899A (en) Verotoxin b subunit for immunization
IE871769L (en) Fluorooxirane carboxylates
CO4820397A1 (es) TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
AU5994596A (en) Administration of valienamine-related disaccharide compounds in reducing inflammation in a sensitized mammal arising fro m exposure to an antigen
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use